Natural killer cells making better cancer immunotherapies

By harvesting stem cells from umbilical cord blood and differentiating them into natural killer cells, Glycostem has developed oNKord, an affordable off-the-shelf cell therapy product indicated for oncology therapies that is ready to ship worldwide within 48hours

Like Comment

Download the Full PDF

Glycostem Therapeutics is at the forefront of efforts to develop safer, more affordable cell therapies which are available off-the-shelf. Instead of work- ing with Tcells, Glycostem is developing naked and engineered natural killer (NK) cells, eliminating the logistical complexity and safety concerns associated with existing therapies.

NK cells have innate advantages over Tcells currently used as chimeric antigen receptor T (CAR-T) therapies on the market. CAR-T cells can cause cytokine release syndrome and for NKcells, clinical reports indicate that this is not a problem, suggesting a more advantageous safety profile than CAR-T cells. Glycostem uses stem cells harvested from umbili- cal cord blood and expands and differentiates them into NK cells. These NK cells are further cryopreserved, resulting in an off-the-shelf cell therapy product called oNKord (Fig. 1). Glycostem can 1-day ship oNKord around the world within 48 hours of receiving an order. The cost of manufacturing is significantly lower than for CAR-Ts and patients would get their treatment sooner.

Those benefits of NK cells are widely recognized but the cells also have limitations that have stopped them coming to market. Notably, NK cells must undergo significant expansion to achieve a thera- peutic dose. Glycostem has overcome that barrier by establishing a proprietary medium and process that expands cell populations by up to 50,000 fold. This has allowed Glycostem to work with feeder- free processes.

Fig.1 | The closed oNKord system.

Validating naked NKcells

Glycostem used the expansion technology to manufacture doses for a phase 1 trial in acute myeloid leukemia (AML). The trial was designed primarily to assess safety and dosing—and generated positive data in those areas—but it also gathered encouraging efficacy results. After 1 year, 80% of patients were alive. Glycostem expected to see a 1-year survival of around 35%.

The clinical data enabled Glycostem to raise money to support the next stage of its develop- ment. Glycostem has set up new state-of-the-art R&D laboratories in the Netherlands and built a good manufacturing practice (GMP)-licensed, fully closed and large-scale production system.

Working out of the GMP facility, which Glycostem thinks is the first of its kind, the team is making cell therapies for a series of planned clinical trials. Glycostem is preparing to run a phase 1/2a clinical trial in minimal residual disease-positive patients with AML. The trial will enrol 33 patients across its two phases, in five countries and eight clinical centres.

In parallel with the AML trial, Glycostem will initiate a phase 2a trial to start testing oNKord in 14 patients with multiple myeloma, which will put Glycostem on track to file for conditional approval of oNKord in two indications in 2023.

Glycostem also plans to initiate a clinical trial of oNKord in solid tumors in 2020. The basket trial will dose patients with NK cells every 3 weeks. The repeat dosing schedule is made possible by the safety of NKcells and the relatively low cost of production. The same trial will shed light on new and improved pre-conditioning agents as well.

A Korean company has licensed the rights to oNKord in its home market and Japan. Glycostem is taking the asset forward in Europe and the USA.

Opening up new indications

The pre-clinical and clinical data generated to date have given Glycostem confidence that naked NK cells work in some indications. However, the company recognizes that it may be necessary to engineer NK cells to treat certain other cancers, such as those affecting the liver, kidney, breast and prostate.

That recognition led Glycostem to hire a team of scientists and task them with genetically modifying NK cells to specifically target tumor cells. These CAR-NK therapies could be powerful enough to cure cancer or turn it into a manageable chronic disease. Other companies are also developing CAR-NKs but Glycostem thinks its extensive experience making and testing naked NKcells will enable it to lead the field. That confidence is validated by deals. Glycostem has a three-asset CAR-NK deal with MolMed and a one-asset agreement with a Korean company, as well as multiple internal programs. As it advances that extensive product pipeline,

Glycostem plans to increasingly align itself with the US market. Preparations for a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration are underway, and Glycostem is also looking to tap into the US market for raw materials. Further down the line, Glycostem may seek US investment.

The planned alignment with the USA reflects Glycostem’s ambitions. Glycostem wants to remain a leading light in NK cell therapies and, as such, has set its sights on the mature, world-leading US market.

Contact:

Troels Jordansen, CEO
Glycostem
Oss, the Netherlands
Tel: +31 618 345 326
Email: troels@glycostem.com
Website: www.glycostem.com

Go to the profile of Glycostem

Glycostem

Glycostem has developed a platform technology for the expansion and differentiation of allogeneic hematopoietic stem and progenitor cells derived from various sources like umbilical cord blood (UCB), bone marrow (BM) or mobilized peripheral blood (mPB). Within the last years, Glycostem's platform technology enables a closed system cell culture process for the expansion of CD34+ hematopoietic stem and progenitor cells and further differentiation into fully functional immune cells, i.e. Natural Killer (NK) cells or antigen presenting cells such as dendritic cells. The technology platform is based on the use of closed bioreactor systems in combination with a proprietary synthetic cell culture medium (GBGM - Glycostem Basal Growth Medium) and a patented combination of growth factors. Glycostem has treated 10 elderly and fragile AML patients in a phase I setting with excellent safety profile and strong indication of clinical efficacy. Year 1 survival data showed 80% compared to population data showing 35%. By late 2019 Glycostem expects to have GMP approved facilities utilising closed system technology resulting is the lowest possible production cost with off the shelf products for our pivotal clinical trial starting early 2020.

No comments yet.